World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
122
Citations
71515
World Ranking
3421
National Ranking
1884

Julio Rosenstock publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Julio Rosenstock sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 600 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Julio Rosenstock D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Julio Rosenstock sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 122 D-Index — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Julio Rosenstock is affiliated with The University of Texas Southwestern Medical Center in the United States. Their research predominantly focuses on the field of medicine, with a substantial emphasis on endocrinology, diabetes, and metabolism. Rosenstock's scholarly contributions cover various subfields including molecular biology, surgery, cardiology and cardiovascular medicine, and pharmacology.

The main topics explored in their research include:

  • Diabetes Treatment and Management
  • Diabetes Management and Research
  • Metabolism, Diabetes, and Cancer
  • Pancreatic function and diabetes
  • Pharmacology and Obesity Treatment
  • Diabetes and associated disorders
  • Cardiovascular Function and Risk Factors

Rosenstock has coauthored extensively with several researchers, among the most frequent collaborators are:

  • Stefano Del Prato
  • Juan P. Frías
  • Vivian Fonseca
  • Melanie J. Davies
  • Ildiko Lingvay

The researcher's work has been published in a range of scientific journals, with recurrent contributions to:

  • Diabetes Obesity and Metabolism
  • Diabetes
  • Diabetologie und Stoffwechsel
  • Diabetes Care
  • New England Journal of Medicine

Some recent papers authored or coauthored by Julio Rosenstock include:

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021, New England Journal of Medicine)
  • Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (2021, New England Journal of Medicine)
  • Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials (2021, The Lancet Diabetes & Endocrinology)
  • Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial (2021, The Lancet)
  • Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (2021, JAMA)

The scope of Rosenstock's research reflects an interdisciplinary approach that integrates diabetes management, obesity treatment, and cardiovascular health through clinical trials and meta-analyses. Their prolific publication record includes over 500 works in medicine, with a significant quantity focused specifically on endocrinology and metabolism topics related to diabetes.

Best Publications

  • Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

    Steven P. Marso;Stephen C. Bain;Agostino Consoli;Freddy G. Eliaschewitz

  • Once-Weekly Semaglutide in Adults with Overweight or Obesity.

    John P.H. Wilding;Rachel L. Batterham;Rachel L. Batterham;Salvatore Calanna;Melanie Davies

  • The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

    Matthew C. Riddle;Julio Rosenstock;John Gerich

  • Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

    John B Buse;Julio Rosenstock;Giorgio Sesti;Wolfgang E Schmidt

  • Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea

    David M. Kendall;Matthew C. Riddle;Julio Rosenstock;Dongliang Zhuang

  • Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients: RIO-North America: A Randomized Controlled Trial

    F. Xavier Pi-Sunyer;Louis J. Aronne;Hassan M. Heshmati;Jeanne Devin

  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

    Julio Rosenstock;Vlado Perkovic;Odd Erik Johansen;Mark E. Cooper

  • Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

    Juan P. Frías;Melanie J. Davies;Julio Rosenstock;Federico C. Pérez Manghi

  • Glimepiride, a New Once-Daily Sulfonylurea: A double-blind placebo-controlled study of NIDDM patients

    Julio Rosenstock;Ellis Samols;Douglas B. Muchmore;Jill Schneider

  • Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial.

    Julio Rosenstock;Michael Tuchman;Linda LaMoreaux;Uma Sharma

  • Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

    Vivian Fonseca;Julio Rosenstock;Rita Patwardhan;Alan Salzman

  • Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

    Naveed Sattar;Matthew M Y Lee;Søren L Kristensen;Kelley R H Branch

  • Basal Insulin Therapy in Type 2 Diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin

    Julio Rosenstock;Sherwyn L. Schwartz;Charles M. Clark;Glen D. Park

  • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

    Julio Rosenstock;Ronald Brazg;Paula J Andryuk;Kaifeng Lu

  • Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors

    Julio Rosenstock;Ele Ferrannini

  • Reduced Hypoglycemia Risk With Insulin Glargine A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

    Julio Rosenstock;George Dailey;Massimo Massi-Benedetti;Andreas Fritsche

  • Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

    Melanie Davies;Louise Færch;Ole K Jeppesen;Arash Pakseresht

  • Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial

    Guntram Schernthaner;Jorge Luiz Gross;Julio Rosenstock;Michael Guarisco

  • Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

    Domenica Rubino;Niclas Abrahamsson;Melanie Davies;Melanie Davies;Dan Hesse

  • Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

    John B Buse;Richard M Bergenstal;Leonard C Glass;Cory R Heilmann

Frequent Co-Authors

Geremia B. Bolli
Geremia B. Bolli University of Perugia
Bernard Zinman
Bernard Zinman University of Toronto
Vivian Fonseca
Vivian Fonseca Tulane University
John B. Buse
John B. Buse University of North Carolina at Chapel Hill
Hans-Juergen Woerle
Hans-Juergen Woerle Nestlé (Switzerland)
Melanie J. Davies
Melanie J. Davies University of Leicester
Nikolaus Marx
Nikolaus Marx RWTH Aachen University
Darren K. McGuire
Darren K. McGuire The University of Texas Southwestern Medical Center
Robert R. Henry
Robert R. Henry University of California, San Diego
William T. Cefalu
William T. Cefalu National Institute of Diabetes and Digestive and Kidney Diseases

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond traditional medical school, several online degree pathways can expand your expertise and open diverse opportunities. Many professionals pursue advanced healthcare management degrees to move into leadership roles. Consider enrolling in one of the top online MHA programs that are CAHME accredited for a flexible, high-quality education in administration.

Nurses seeking career advancement without the need for additional clinical hours can explore online RN to BSN no clinicals programs. These offerings are ideal for working RNs who want to earn their bachelor's degree efficiently and conveniently.

If you aim for the highest levels of clinical practice, doctoral programs are available entirely online. Options like accelerated DNP programs online let experienced nurses earn a Doctor of Nursing Practice degree in less time. There are also flexible DNP programs designed for various learning preferences and schedules.

Online pathways support career growth while allowing you to balance work and study, making them strong alternatives or complements to traditional medical education in the USA.

Best Scientists Citing Julio Rosenstock

Trending Scientists

Recently Published Articles